72
Participants
Start Date
December 29, 2022
Primary Completion Date
May 8, 2025
Study Completion Date
May 8, 2025
Placebo
Placebo will be administered subcutaneously as two injections for each dose.
Daxdilimab
Daxdilimab will be administered subcutaneously as two injections for each dose.
Ambulatory for specialized medical care - individual practice for specialized medical care - skin and venereal diseases, Sofia
"DCC Alexandrovska EOOD", Sofia
Medical Center Eurohealth EOOD, Sofia
Bispebjerg Hospital, Dermato-Venerologisk Afdeling Og Videncenter for Sårheling, D/S., Copenhagen NV
Sjællands Universitetshospital, Roskilde
OUH, Odense C
Service de dermatologie, hôpital Archet 2, CHU NICE, Nice Alpes
DCC 'Sveti Georgi' EOOD, Haskovo
Charité - Universitätsmedizin Berlin, Berlin
"General Hospital of Athens Evangelismos", Athens
Forest Hills Dermatology, Forest Hills
401 General Military Hospital of Athens, Athens
"University General Hospital Attikon", Athens
BAG Dr. Freitag und Knöll, Falkensee
Andreas Syggros Hospital, Athens
Paddington Testing Company, Inc., Philadelphia
Autoimmune Skin Diseases Unit, Dept. of Dermatology, Philadelphia
Klinikum Oldenburg AöR, Oldenburg
Miami Dermatology & Laser Research, Miami
University General Hospital of Larissa, Larissa
Ohio State University, Columbus
Wright State Physicians, Fairborn
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Michigan Dermatology Institute, Waterford
Detroit Clinical Research Center, PC, Farmington Hills
Minnesota Clinical Study Center, New Brighton
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz
General Hospital Papageorgiou, Thessaloniki
MediSearch Clinical Trials, Saint Joseph
Hopital Edouard Herriot - CHU Lyon, Lyon
Universitaetsklinikum Tuebingen, Tübingen
Arkansas Research Trials, North Little Rock
CHU de Rouen - Hôpital Charles Nicolle, Rouen
Center for Clinical Studies (Cypress), Houston
CHU Poitiers - Hôpital la Milétrie, Poitiers
Wallace Medical Group, Beverly Hills
Clinical Science Institute, Santa Monica
The Center for Dermatology Clinical Research, Fremont
Fundacion Scherbovsky, Mendoza
CIPREC, Ciudad Autonoma Buenos Aires
HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará, Fortaleza
Hospital Universitário Evangélico Mackenzie, Água Verde
Fundação Faculdade Regional de Medicina de São José do Rio Preto, CIP - Centro Integrado de Pesquisa, Sao Jose Rio
Complexo Hospitalar de Niterói, Niterói
Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A, Rio de Janeiro
Fundação Universidade de Caxias do Sul - Instituto de Pesquisas em Saúde da Universidade de Caxias do Sul, Caxias do Sul
Hospital Moinhos de Vento, Porto Alegre
Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre
LMK Serviços Médicos S/S, Porto Alegre
Universidade Estadual de Campinas, Campinas
Hospital Christovão da Gama - Centro de Estudos, Santo André
Centro Multidisciplinar de Estudos Clinicos, São Bernardo do Campo
IMC - Instituto de Moléstias Cardiovasculares Tatuí, Tatuí
IPITEC Instituto de Pesquisa Inovação Tecnológica, São Paulo
Alberta DermaSurgery Centre, Edmonton
Brunswick Dermatology Center, Fredericton
DermEffects, London
North York Research, Inc, Toronto
K. Papp Clinical Research, Waterloo
Fakultni nemocnice u sv. Anny v Brne, Brno
Sanatorium Profesora Arenbergera, Prague
Universitätsklinikum Carl Gustav Carus TU Dresden, Klinik und Poliklinik f. Dermatologie, Dresden
Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy Marek Brzewski, Pawel Brzewski Spolka Cywilna, Krakow
Centrum Badawcze Panaceum Agnieszka Brzezicka Magdalena Lenkiewicz Sp. z o.o., Malbork
Kliniczny Szpital Wojewodzki nr 1 im.F.Chopina, Rzeszów
LASER CLINIC S.C. Dr Tomasz Kochanowski Dr Andrzej Krolicki, Szczecin
Clinical Research Group Sp. z o.o., Warsaw
Centralny Szpital Kliniczny MSWiA, Warsaw
Lead Sponsor
Amgen
INDUSTRY